Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2010

01-01-2010 | Letter

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]

Authors: U. Grouven, L. G. Hemkens, R. Bender, P. T. Sawicki

Published in: Diabetologia | Issue 1/2010

Login to get access

Excerpt

To the Editor: Nagel et al. [1] raise a number of questions regarding the analyses in our paper [2]; these analyses, in their opinion, led to confounded measures of association. We agree that potential confounding plays an essential role and can never be completely ruled out in analyses of observational data. However, we do not agree that the possibility of confounding inevitably leads to the conclusion that such results are definitely wrong and cannot reflect real risks. …
Literature
1.
2.
Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefPubMed
3.
Thefeld W (1999) Prevalence of diabetes mellitus among adults in Germany. Gesundheitswesen 61:S85–S89 (article in German)PubMed
4.
Andersen PK, Abidstrom SZ, Rosthøj S (2002) Competing risks as a multi-state model. Stat Methods Med Res 11:203–215CrossRefPubMed
5.
Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18:695–706CrossRefPubMed
6.
Pocock SJ, Smeeth L (2009) Insulin glargine and malignancy: an unwarranted alarm. Lancet 374:511–513CrossRefPubMed
7.
Hemkens LG, Grouven U, Bender R, Sawicki PT. Response to Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009 (in press).
8.
9.
Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005CrossRefPubMed
10.
11.
12.
Bundesärztekammer (Arbeitsgemeinschaft der Deutschen Ärztekammern), Arzneimittelkommission der deutschen Ärzteschaft, Deutsche Diabetes Gesellschaft, Fachkommission Diabetes Sachsen, Deutsche Gesellschaft für Innere Medizin, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (eds) Nationale Versorgungsleitlinie Typ 2 Diabetes mellitus (Stand April 2003) Kurzfassung. National Guideline Type 2 Diabetes Mellitus (April 2003) Short Version. Available from www.​versorgungsleitl​inien.​de/​themen/​pdf/​nvldiabetes.​pdf, accessed 29 September 2009 (article in German)
13.
Metadata
Title
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]
Authors
U. Grouven
L. G. Hemkens
R. Bender
P. T. Sawicki
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1582-6

Other articles of this Issue 1/2010

Diabetologia 1/2010 Go to the issue

Article

Association of existing diabetes, gestational diabetes and glycosuria in pregnancy with macrosomia and offspring body mass index, waist and fat mass in later childhood: findings from a prospective pregnancy cohort

Article

Diabetes regulates mitochondrial biogenesis and fission in mouse neurons

Article

HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study

Article

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

Commentary

Leptin therapy in lipodystrophy

Letter

Insulin resistance and increased risk for malignant neoplasms: confounding of the data on insulin glargine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits